Holista Colltech Limited

HCT.ASX

Consumer Staples

Bio-industrial company committed to the development and commercialisation of food ingredients and ovine collagen for cosmetic and biomedical applications.

Market Data

Price

$0.075

+0.0%
Market Cap

$27.2M

P/E Ratio

-100000.0x

EPS

$-0.003

Div. Yield

0.00%

52-Week Change

-0.1%

Latest Earnings

Appendix 4E - Preliminary Final Report

27 February 2026

Revenue
$5.76
+3.0% YoY
NPAT
-$0.95
-1026.8% YoY
EPS
$-0.00

Holista Colltech reported FY2025 revenue growth of 3% to $5.8M, driven by Dietary Supplements (+11.4%) and favourable FX, with gross margins improving to 45%. However, the company recorded a net loss of $949K, significantly impacted by $1.09M ASIC legal settlement costs and $394K ProImmune legal expenses, partially offset by $842K debt recoveries. Management is pursuing growth initiatives including a B2C pivot, new Collie manufacturing facility (commencing 2H 2026), and strategic partnerships with Regenerex Pharma for global collagen markets. Key points: Gross margin improved to 45% (FY2024: 42%) through FX tailwinds and cost discipline; Dietary Supplements segment grew 11.4% to $5.22M, offsetting Food Ingredients decline and providing core growth driver; Successfully raised $3.85M in capital during FY2025 ($1.53M convertible notes + $2.3M placement) to strengthen balance sheet

Recent Announcements

27 Feb 2026 Actual Results Neutral

Appendix 4E - Preliminary Final Report

Holista Colltech reported FY2025 revenue growth of 3% to $5.8M, driven by Dietary Supplements (+11.4%) and favourable FX, with gross margins improving to 45%. However, the company recorded a net loss of $949K, significantly impacted by $1.09M ASIC legal settlement costs and $394K ProImmune legal expenses, partially offset by $842K debt recoveries. Management is pursuing growth initiatives including a B2C pivot, new Collie manufacturing facility (commencing 2H 2026), and strategic partnerships with Regenerex Pharma for global collagen markets. Key points: Gross margin improved to 45% (FY2024: 42%) through FX tailwinds and cost discipline; Dietary Supplements segment grew 11.4% to $5.22M, offsetting Food Ingredients decline and providing core growth driver; Successfully raised $3.85M in capital during FY2025 ($1.53M convertible notes + $2.3M placement) to strengthen balance sheet

Get real-time alerts for HCT

Receive AI-powered earnings summaries and instant notifications when Holista Colltech Limited releases results.

Register Free